TY  - GEN
AU  - Hillmen,Peter
AU  - Cohen,Dena R
AU  - Cocks,Kim
AU  - Pettitt,Andrew
AU  - Sayala,Hazem A
AU  - Rawstron,Andy C
AU  - Kennedy,Daniel B
AU  - Fegan,Christopher
AU  - Milligan,Don W
AU  - Radford,John
AU  - Mercieca,Jane
AU  - Dearden,Claire
AU  - Ezekwisili,Raphael
AU  - Smith,Alexandra F
AU  - Brown,Julia
AU  - Booth,Gillian A
AU  - Varghese,Abraham M
AU  - Pocock,Christopher
TI  - A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
SN  - 1365-2141
PY  - 2011///0512
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cyclophosphamide
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Mitoxantrone
KW  - Neoplasm, Residual
KW  - Rituximab
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Vidarabine
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/j.1365-2141.2010.08317.x
ER  -